Search

Your search keyword '"Gay, Francesca"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Gay, Francesca" Remove constraint Author: "Gay, Francesca" Topic antineoplastic combined chemotherapy protocols Remove constraint Topic: antineoplastic combined chemotherapy protocols
41 results on '"Gay, Francesca"'

Search Results

1. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

2. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.

3. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.

4. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.

5. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR.

6. Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing.

7. Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

8. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.

9. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.

10. Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

11. Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.

12. Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.

13. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.

14. Stem Cell Transplantation in Multiple Myeloma.

15. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

16. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

17. Autologous transplantation and maintenance therapy in multiple myeloma.

18. Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.

19. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.

20. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.

21. Management of myeloma: an Italian perspective.

22. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.

23. Management of older patients with multiple myeloma.

24. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.

25. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.

26. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.

27. Management of disease- and treatment-related complications in patients with multiple myeloma.

28. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.

29. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

30. Towards a new standard of care for patients with myeloma?

31. First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective.

32. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.

33. How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.

34. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

35. Update on recent developments for patients with newly diagnosed multiple myeloma.

36. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.

37. Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.

38. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

39. Multiple myeloma: management of adverse events

40. Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

41. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma

Catalog

Books, media, physical & digital resources